Syngulon is a synthetic biology startup developing original genetic technologies using bacteriocins. We harness the unique properties of bacteriocins to engineer innovative genetic technologies that address some of the most pressing challenges in biotechnology and health.

Our technology portfolio is structured around two core applications in relation with health:
1) Antibiotic-free genetic selection – sustainable alternatives to antibiotic resistance markers for recombinant protein production.
2) Next-generation antimicrobials – novel bacteriocin-based molecules offering targeted strategies against resistant pathogens identified by WHO.